CA
Therapeutic Areas
Zymeworks Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Zanidatamab (ZW25) | HER2-positive biliary tract cancers (BTC) | Phase 2b |
| ZW171 | TA-MUC1-positive solid tumors (e.g., ovarian cancer) | Phase 1 |
| ZW191 | FRα-positive solid tumors (e.g., ovarian cancer) | Phase 1 |
| ZW220 | Advanced solid tumors | Preclinical |
Leadership Team at Zymeworks
KG
Kenneth Galbraith
Chair & Chief Executive Officer
NK
Neil Klompas
President, Chief Operating & Financial Officer
NJ
Neil Josephson
Chief Medical Officer
PM
Paul Moore
Chief Scientific Officer
LZ
Lota Zoth
Senior Vice President, Chief Accounting Officer
AT
Ali Tehrani
Founder and former President & CEO
AP
Anthony Polverino
Board Member
KN
Kelvin Neu
Board Member